Some people get absolutely no pain relief from codeine because their body literally cannot convert it into morphine, which is the compound that actually does the work. Codeine itself is essentially a prodrug — pharmacologically inactive until liver enzymes transform it into its active form. The enzyme responsible for this conversion is called CYP2D6, and roughly five to ten percent of people of European descent carry genetic variants that leave this enzyme nonfunctional. These individuals, classified as “poor metabolizers,” can swallow codeine all day long and never experience meaningful analgesia. It is not a matter of pain tolerance, mental toughness, or drug-seeking behavior.
It is straightforward biochemistry. This genetic variability has serious implications that extend well beyond a single prescription. For families dealing with dementia care, where managing pain in someone who may not be able to clearly articulate what they are feeling is already a profound challenge, understanding why a prescribed analgesic might silently fail matters enormously. A caregiver who assumes the codeine is working because the doctor ordered it may miss signs of ongoing, untreated pain in a loved one with cognitive decline. This article explains the science behind CYP2D6 metabolism, who is most affected, what the risks look like on both ends of the spectrum, and what practical alternatives exist when codeine turns out to be the wrong tool for the job.
Table of Contents
- Why Does Codeine Fail to Relieve Pain in Some People?
- How CYP2D6 Genetic Variants Differ Across Populations
- The Ultrarapid Metabolizer Problem — When Codeine Becomes Dangerous
- Pharmacogenomic Testing — What It Is and When It Makes Sense
- Why Untreated Pain in Dementia Patients Is Especially Harmful
- Alternative Pain Medications When Codeine Is Ineffective
- The Future of Personalized Pain Management
- Conclusion
- Frequently Asked Questions
Why Does Codeine Fail to Relieve Pain in Some People?
Codeine belongs to a class of medications called prodrugs, meaning it must be metabolized by the body before it becomes therapeutically active. When you take a codeine tablet, your liver uses the cytochrome P450 enzyme CYP2D6 to demethylate codeine into morphine. It is the morphine — not the codeine — that binds to opioid receptors in the brain and spinal cord to dampen pain signaling. If your CYP2D6 enzyme is absent or barely functional due to inherited genetic variations, this conversion does not happen in any clinically meaningful way. You might as well be taking a sugar pill, except with the added insult of side effects like constipation and nausea that can occur independently of the analgesic pathway. The CYP2D6 gene is one of the most polymorphic genes in the entire human genome. Researchers have identified well over a hundred distinct allelic variants, and these variants produce a spectrum of enzyme activity. People are generally categorized into four metabolizer phenotypes: poor, intermediate, extensive (now often called “normal”), and ultrarapid.
Poor metabolizers carry two nonfunctional alleles and produce essentially no working enzyme. Consider a practical example: two patients recovering from the same dental extraction both receive a standard codeine prescription. One gets adequate relief within forty minutes. The other feels nothing hours later and ends up back in the clinic frustrated, possibly suspected of exaggerating or seeking stronger drugs. The difference between them may come down entirely to which CYP2D6 alleles they inherited from their parents. Intermediate metabolizers, who carry one reduced-function and one nonfunctional allele, or two reduced-function alleles, occupy a gray zone. They may get some conversion of codeine to morphine, but often not enough for reliable pain control. This partial response can be particularly confusing for clinicians and patients alike because the drug appears to “sort of” work, leading to dose escalation that increases side effects without proportionally improving pain relief.
How CYP2D6 Genetic Variants Differ Across Populations
The frequency of CYP2D6 poor metabolizer status varies significantly by ethnic and geographic background, which means this is not a one-size-fits-all problem. Studies have historically estimated that around five to ten percent of white European populations are poor metabolizers. In East Asian populations, the prevalence of nonfunctional alleles tends to be somewhat lower, though reduced-function alleles are more common, resulting in a higher proportion of intermediate metabolizers. Among some North African and Middle Eastern populations, ultrarapid metabolizer status — the opposite end of the spectrum, which carries its own dangers — has been reported at notably higher rates, though exact figures vary across studies. These population-level statistics, however, come with an important caveat. Individual genetics do not follow group averages. A person of any background can carry any combination of CYP2D6 alleles.
Relying on ethnic generalizations to make prescribing decisions would be both scientifically lazy and clinically dangerous. The only reliable way to know someone’s metabolizer status is through pharmacogenomic testing, which analyzes the specific alleles a person carries. Without testing, a clinician is essentially guessing — an educated guess informed by population data, perhaps, but a guess nonetheless. There is also a compounding factor that matters for dementia care specifically. Older adults are frequently on multiple medications, and several common drugs are known CYP2D6 inhibitors. Certain antidepressants, including fluoxetine and paroxetine, can functionally convert a normal metabolizer into a poor one by blocking the enzyme. If a dementia patient is already taking one of these medications, codeine may fail even if their underlying genetics would otherwise support normal metabolism. This drug-drug interaction is sometimes called phenoconversion, and it is underappreciated in clinical practice.
The Ultrarapid Metabolizer Problem — When Codeine Becomes Dangerous
While poor metabolizers get no benefit from codeine, people at the other extreme face a different and potentially lethal problem. Ultrarapid metabolizers carry multiple functional copies of the CYP2D6 gene, sometimes three or four copies on a single chromosome, and they convert codeine into morphine at an accelerated rate. This means a standard dose can produce morphine blood levels far exceeding what is expected, leading to respiratory depression, profound sedation, and in documented cases, death. The most harrowing examples have involved children. Regulatory agencies in multiple countries issued safety communications after reports of pediatric deaths linked to codeine use in ultrarapid metabolizers, particularly following tonsillectomy and adenoidectomy procedures. One widely reported case involved a toddler who died after receiving what should have been a safe, weight-appropriate codeine dose prescribed to his breastfeeding mother, who turned out to be an ultrarapid metabolizer.
The morphine concentrated in her breast milk at toxic levels. These tragedies prompted the U.S. Food and Drug Administration and similar agencies to restrict or contraindicate codeine use in children, though the underlying genetic risk applies to adults as well. For dementia caregivers, this is worth understanding even if their loved one is not a child. An older adult with ultrarapid metabolizer status who receives codeine could experience excessive sedation that mimics or worsens cognitive decline, increasing fall risk, confusion, and respiratory complications. In someone already living with dementia, these effects might be attributed to disease progression rather than recognized as an adverse drug reaction, delaying appropriate intervention.
Pharmacogenomic Testing — What It Is and When It Makes Sense
Pharmacogenomic testing for CYP2D6 and other drug-metabolizing enzymes has become increasingly accessible and is now offered by numerous commercial laboratories and some health systems. The test typically requires only a cheek swab or blood sample and returns results that classify the patient’s predicted metabolizer phenotype. Several major medical institutions and professional organizations, including the Clinical Pharmacogenetics Implementation Consortium, have published guidelines that recommend using CYP2D6 results to guide codeine prescribing when available. The tradeoff, as with most medical decisions, involves cost, access, and clinical workflow. Pharmacogenomic tests can range in price and may or may not be covered by insurance depending on the indication and the payer. For a patient who has already demonstrated a poor response to codeine, the practical value of confirming the genetic reason may be limited if the clinician simply switches to an alternative analgesic.
However, the broader value of knowing a patient’s CYP2D6 status extends beyond codeine alone. The same enzyme metabolizes tramadol, certain antidepressants, tamoxifen, some beta-blockers, and numerous other medications. For an older adult with dementia who is likely to encounter multiple prescriptions over time, a one-time pharmacogenomic test can inform years of prescribing decisions. The argument against routine testing in every patient usually comes down to cost-effectiveness at the population level. But for individuals who have experienced unexplained medication failures, unusual side effects, or who are taking multiple CYP2D6-dependent drugs, the case for testing grows considerably stronger. Caregivers advocating for a family member with dementia may find it worthwhile to discuss pharmacogenomic testing with their loved one’s physician, particularly if pain management has been inconsistent or difficult.
Why Untreated Pain in Dementia Patients Is Especially Harmful
The intersection of failed codeine therapy and dementia care deserves particular attention because untreated pain in people with cognitive impairment is both common and deeply damaging. Research has consistently shown that dementia patients receive less pain medication than cognitively intact individuals with similar conditions, partly because they may be unable to report pain using standard verbal scales. When a medication that was prescribed to address pain silently fails due to pharmacogenetic factors, the gap widens further. Untreated pain in dementia frequently manifests as behavioral symptoms — agitation, aggression, withdrawal, resisting care, disrupted sleep, and vocalizations that may be misinterpreted as symptoms of the dementia itself.
This can trigger a harmful cascade: the behavioral symptoms get treated with antipsychotics or sedatives, which carry their own serious risks in elderly patients including increased mortality, while the underlying pain remains unaddressed. A caregiver or clinician who understands that codeine might not be working due to genetic or drug-interaction reasons is better positioned to advocate for reassessment rather than simply layering on additional medications. It is also worth noting that pain itself may accelerate cognitive decline. While the research in this area is still evolving, chronic unmanaged pain is associated with increased stress hormones, sleep disruption, and reduced engagement in physical and social activities — all factors that can worsen dementia trajectories. Ensuring that pain medication is actually working, rather than assuming it is, becomes a meaningful component of comprehensive dementia care.
Alternative Pain Medications When Codeine Is Ineffective
When codeine is off the table, clinicians have several alternative pathways depending on the type and severity of pain. For mild to moderate pain, non-opioid options like acetaminophen (paracetamol) remain a first-line choice and do not depend on CYP2D6 metabolism. Nonsteroidal anti-inflammatory drugs such as ibuprofen or naproxen can be effective for inflammatory pain, though they carry gastrointestinal and cardiovascular risks that require careful consideration in older adults.
For neuropathic pain, medications like gabapentin or pregabalin work through entirely different mechanisms and bypass the opioid pathway altogether. If opioid-level analgesia is genuinely needed, morphine itself — rather than the prodrug codeine — can be prescribed directly, eliminating the metabolic conversion problem. Oxycodone is partially metabolized by CYP2D6 but also has direct analgesic activity, making it less dependent on that single enzyme. However, any opioid use in older adults with dementia requires cautious dosing and close monitoring given the heightened risks of sedation, falls, and respiratory depression in this population.
The Future of Personalized Pain Management
The broader trend in medicine is moving toward pharmacogenomics becoming a routine part of care rather than an afterthought triggered by drug failure. Some health systems have begun implementing preemptive pharmacogenomic testing, where a panel of drug-metabolizing genes is analyzed early — sometimes at the point of enrollment — and results are embedded in the electronic health record so they are available whenever a new prescription is written.
This approach has the potential to prevent the trial-and-error prescribing that costs patients time, comfort, and trust. For dementia care specifically, where communication barriers make it harder to detect when a medication is not working, preemptive genetic information could be particularly valuable. As testing costs continue to decline and clinical decision support tools improve, the hope is that no patient — especially one who cannot easily speak up for themselves — will be left in pain because of a predictable and preventable pharmacogenetic mismatch.
Conclusion
Codeine’s failure in a significant minority of people is not a mystery or a matter of perception. It is a well-characterized genetic phenomenon rooted in the CYP2D6 enzyme system, and it affects millions of people worldwide. For those who are poor metabolizers, codeine provides no analgesic benefit whatsoever. For ultrarapid metabolizers, it can be outright dangerous.
The intermediate metabolizers in between may experience unpredictable, partial responses that complicate pain management without fully resolving it. For families navigating dementia care, where the person in pain may not be able to clearly say the medication is not working, this knowledge is not academic — it is practical and urgent. Caregivers should feel empowered to ask prescribing physicians whether pharmacogenomic testing has been considered, whether drug interactions might be inhibiting codeine metabolism, and whether alternative analgesics might be more reliable. Pain that goes unrecognized or untreated in dementia does real harm, and ensuring that prescribed medications can actually do their job is one of the most concrete steps caregivers and clinicians can take together.
Frequently Asked Questions
How do I know if I or my family member is a CYP2D6 poor metabolizer?
The only definitive way is through pharmacogenomic testing, which can be ordered by a physician and typically involves a simple cheek swab or blood draw. A history of codeine or tramadol providing no pain relief despite adequate dosing is a clinical clue, but genetic testing confirms the metabolizer status and provides information useful for many other medications as well.
Can a doctor tell from looking at someone whether codeine will work for them?
No. CYP2D6 metabolizer status cannot be determined by physical appearance, ethnicity, age, or any external characteristic. While population-level data shows varying frequencies of poor metabolizer status across ethnic groups, individual genetics must be assessed through laboratory testing. Assumptions based on demographics are unreliable and inappropriate.
Is tramadol affected by the same genetic issue as codeine?
Yes. Tramadol is also a prodrug that relies on CYP2D6 to be converted into its active metabolite, O-desmethyltramadol. A person who is a CYP2D6 poor metabolizer will generally get inadequate pain relief from both codeine and tramadol for the same enzymatic reason.
If codeine does not work, does that mean all opioids will fail?
No. Codeine and tramadol specifically depend on CYP2D6 conversion to be effective. Other opioids such as morphine, hydromorphone, and fentanyl are already in their active forms and do not require this metabolic step. Oxycodone is partially metabolized by CYP2D6 but retains significant direct activity. Alternative opioids can be effective even in CYP2D6 poor metabolizers, though all opioid prescribing in older adults requires careful risk assessment.
Should every dementia patient get pharmacogenomic testing?
There is no universal mandate, but a strong clinical argument can be made for it. Dementia patients often take multiple medications affected by CYP2D6 and other polymorphic enzymes, and their ability to report medication ineffectiveness or side effects is compromised. A one-time test can inform prescribing decisions across many drug classes for the remainder of the patient’s life.
Can other medications I take block CYP2D6 and make codeine stop working?
Yes. Several commonly prescribed drugs are potent CYP2D6 inhibitors, including the antidepressants fluoxetine (Prozac) and paroxetine (Paxil), as well as bupropion and some others. Taking these medications can effectively turn a normal metabolizer into a poor one — a phenomenon called phenoconversion — rendering codeine ineffective even in someone whose genetics would otherwise support normal metabolism.
